Dana E. Selley - Publications

Pharmacology & Toxicology Virginia Commonwealth University, Richmond, VA, United States 
Pharmacology, Molecular Biology

126 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Pagare PP, Li M, Zheng Y, Kulkarni AS, Obeng S, Huang B, Ruiz C, Gillespie JC, Mendez RE, Stevens DL, Poklis JL, Halquist MS, Dewey WL, Selley DE, Zhang Y. Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists. Journal of Medicinal Chemistry. PMID 35255685 DOI: 10.1021/acs.jmedchem.2c00087  0.429
2022 Huang B, Li M, Klongkumnuankarn P, Mendez RE, Gillespie JC, Stevens DL, Dewey WL, Selley DE, Zhang Y. Rational Design, Chemical Syntheses, and Biological Evaluations of Peripherally Selective Mu Opioid Receptor Ligands as Potential Opioid Induced Constipation Treatment. Journal of Medicinal Chemistry. PMID 35255683 DOI: 10.1021/acs.jmedchem.1c02185  0.402
2022 Ma H, Li M, Pagare PP, Wang H, Nassehi N, Santos EJ, Stevens Negus S, Selley DE, Zhang Y. Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimers. Bioorganic Chemistry. 120: 105641. PMID 35093692 DOI: 10.1016/j.bioorg.2022.105641  0.47
2021 Huang B, Wang H, Zheng Y, Li M, Kang G, Barreto-de-Souza V, Nassehi N, Knapp PE, Selley DE, Hauser KF, Zhang Y. Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity. Journal of Medicinal Chemistry. PMID 34027668 DOI: 10.1021/acs.jmedchem.1c00408  0.34
2021 Ma H, Wang H, Gillespie JC, Mendez RE, Selley DE, Zhang Y. Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptor. Bioorganic & Medicinal Chemistry Letters. 127953. PMID 33766769 DOI: 10.1016/j.bmcl.2021.127953  0.412
2021 Huang B, Gunta R, Wang H, Li M, Cao D, Mendez RE, Gillespie JC, Chen C, Huang LM, Liu-Chen LY, Selley DE, Zhang Y. Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors. Bioorganic Chemistry. 109: 104702. PMID 33631465 DOI: 10.1016/j.bioorg.2021.104702  0.414
2021 Wang H, Cao D, Gillespie JC, Mendez RE, Selley DE, Liu-Chen LY, Zhang Y. Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators. Future Medicinal Chemistry. PMID 33590767 DOI: 10.4155/fmc-2020-0308  0.413
2020 Reinecke BA, Kang G, Zheng Y, Obeng S, Zhang H, Selley DE, An J, Zhang Y. Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimer. Rsc Medicinal Chemistry. 11: 125-131. PMID 33479612 DOI: 10.1039/c9md00433e  0.392
2020 Selley DE, Banks ML, Diester CM, Jali AM, Legakis LP, Santos EJ, Negus SS. . The Journal of Pharmacology and Experimental Therapeutics. PMID 33443077 DOI: 10.1124/jpet.120.000349  0.496
2020 Ma H, Wang H, Li M, Barreto-de-Souza V, Reinecke BA, Gunta R, Zheng Y, Kang G, Nassehi N, Zhang H, An J, Selley DE, Hauser KF, Zhang Y. Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry. Acs Medicinal Chemistry Letters. 11: 2318-2324. PMID 33214847 DOI: 10.1021/Acsmedchemlett.0C00444  0.515
2020 Meade JA, Alkhlaif Y, Contreras KM, Obeng S, Toma W, Sim-Selley LJ, Selley DE, Damaj MI. Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathy. Psychopharmacology. PMID 32529265 DOI: 10.1007/S00213-020-05572-2  0.447
2020 Selley DE, Lazenka MF, Sim-Selley LJ, Secor McVoy JR, Potter DN, Chartoff EH, Carlezon WA, Negus SS. Attenuated dopamine receptor signaling in nucleus accumbens core in a rat model of chemically-induced neuropathy. Neuropharmacology. 166: 107935. PMID 31917153 DOI: 10.1016/J.Neuropharm.2020.107935  0.431
2019 Ma H, Obeng S, Wang H, Zheng Y, Li M, Jali AM, Stevens D, Dewey WL, Selley DE, Zhang Y. Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators. Journal of Medicinal Chemistry. PMID 31782922 DOI: 10.1021/Acs.Jmedchem.9B01767  0.513
2019 Zheng Y, Obeng S, Reinecke BA, Chen C, Phansalkar PS, Walentiny DM, Gerk PM, Liu-Chen LY, Selley DE, Beardsley PM, Zhang Y. Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder. European Journal of Pharmacology. 172812. PMID 31743739 DOI: 10.1016/J.Ejphar.2019.172812  0.464
2019 Khan MM, Xiao J, Hollingsworth TJ, Patel D, Selley DE, Ring TL, LeDoux MS. Gnal haploinsufficiency causes genomic instability and increased sensitivity to haloperidol. Experimental Neurology. PMID 31034808 DOI: 10.1016/J.Expneurol.2019.04.014  0.373
2019 Obeng S, Jali A, Zheng Y, Wang H, Schwienteck K, Chen C, Stevens DL, Akbarali H, Dewey WL, Banks ML, Liu-Chen LY, Selley DE, Zhang Y. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment. Acs Chemical Neuroscience. PMID 30758946 DOI: 10.1021/Acschemneuro.9B00038  0.528
2019 Zheng Y, Obeng S, Wang H, Jali AM, Peddibhotla B, Williams D, Zou C, Stevens DL, Dewey WL, Akbarali HI, Selley DE, Zhang Y. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'- pyridyl)carboxamido]morphinan (NAP) Derivatives as Mu/Kappa Opioid Receptor Dual Selective Ligands. Journal of Medicinal Chemistry. PMID 30608693 DOI: 10.1021/Acs.Jmedchem.8B01158  0.5
2018 Obeng S, Wang H, Jali A, Stevens DL, Akbarali HI, Dewey WL, Selley DE, Zhang Y. Structure activity relationship studies of 6α- and 6β-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the 'message-address concept' to comprehend their functional conversion. Acs Chemical Neuroscience. PMID 30156823 DOI: 10.1021/Acschemneuro.8B00349  0.464
2018 Kota D, Alajaji M, Bagdas D, Selley DE, Sim-Selley LJ, Imad Damaj M. Early adolescent nicotine exposure affects later-life hippocampal mu-opioid receptors activity and morphine reward but not physical dependence in male mice. Pharmacology, Biochemistry, and Behavior. PMID 30125591 DOI: 10.1016/J.Pbb.2018.08.006  0.426
2018 Zheng Y, Obeng S, Wang H, Stevens DL, Komla E, Selley DE, Dewey WL, Akbarali HI, Zhang Y. Methylation Products of 6β-N-heterocyclic substituted naltrexamine derivatives as potential peripheral opioid receptor modulators. Acs Chemical Neuroscience. PMID 30001114 DOI: 10.1021/Acschemneuro.8B00234  0.563
2018 Sim-Selley LJ, Wilkerson JL, Burston JJ, Hauser KF, McLane V, Welch SP, Lichtman AH, Selley DE. Differential Tolerance to FTY720-induced Antinociception in Acute Thermal and Nerve Injury Mouse Pain Models: Role of S1P Receptor Adaptation. The Journal of Pharmacology and Experimental Therapeutics. PMID 29945931 DOI: 10.1124/Jpet.118.248260  0.447
2018 Obeng S, Yuan Y, Jali A, Selley DE, Zhang Y. In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator. European Journal of Pharmacology. PMID 29530590 DOI: 10.1016/J.Ejphar.2018.03.013  0.489
2017 Xu GG, Zolotarskaya OY, Williams DA, Yuan Y, Selley DE, Dewey WL, Akbarali HI, Yang H, Zhang Y. Nanoconjugated NAP as a Potent and Periphery Selective Mu Opioid Receptor Modulator To Treat Opioid-Induced Constipation. Acs Medicinal Chemistry Letters. 8: 78-83. PMID 28105279 DOI: 10.1021/Acsmedchemlett.6B00382  0.507
2016 Blume LC, Patten T, Eldeeb K, Leone-Kabler S, Ilyasov AA, Keegan BM, O'Neal JE, Bass CE, Hantgan RR, Lowther WT, Selley DE, Howlett AC. Cannabinoid Receptor Interacting Protein (CRIP) 1a competition with β-arrestin for CB1 receptor binding sites. Molecular Pharmacology. PMID 27895162 DOI: 10.1124/Mol.116.104638  0.371
2016 Arnatt CK, Falls BA, Yuan Y, Raborg TJ, Masvekar RR, El-Hage N, Selley DE, Nicola AV, Knapp PE, Hauser KF, Zhang Y. Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization. Bioorganic & Medicinal Chemistry. PMID 27720326 DOI: 10.1016/J.Bmc.2016.09.059  0.447
2016 Grim TW, Morales AJ, Gonek MM, Wiley JL, Thomas BF, Endres GW, Sim-Selley LJ, Selley DE, Negus SS, Lichtman AH. Stratification of cannabinoid 1 receptor (CB1R) agonist efficacy: Manipulation of CB1R density through use of transgenic mice reveals congruence between in vivo and in vitro assays. The Journal of Pharmacology and Experimental Therapeutics. PMID 27535976 DOI: 10.1124/Jpet.116.233163  0.478
2016 Blume LC, Leone-Kabler S, Luessen DJ, Marrs GS, Lyons E, Bass CE, Chen R, Selley DE, Howlett AC. Cannabinoid Receptor Interacting Protein (CRIP1a) suppresses agonist-driven CB1 receptor internalization, and regulates receptor replenishment in an agonist-biased manner. Journal of Neurochemistry. PMID 27513693 DOI: 10.1111/Jnc.13767  0.465
2016 Owens RA, Ignatowska-Jankowska BM, Mustafa M, Beardsley PM, Wiley JL, Jali A, Selley DE, Niphakis M, Cravatt BF, Lichtman AH. Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice. The Journal of Pharmacology and Experimental Therapeutics. PMID 27307500 DOI: 10.1124/Jpet.115.229492  0.395
2016 Williams DA, Zheng Y, David BG, Yuan Y, Zaidi SA, Stevens DL, Scoggins KL, Selley DE, Dewey WL, Akbarali HI, Zhang Y. 6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand. Acs Chemical Neuroscience. PMID 27269866 DOI: 10.1021/Acschemneuro.6B00075  0.508
2016 Grim TW, Samano KL, Ignatowska-Jankowska B, Tao Q, Sim-Selly LJ, Selley DE, Wise LE, Poklis A, Lichtman AH. Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497. Journal of Basic and Clinical Physiology and Pharmacology. 27: 217-28. PMID 27149200 DOI: 10.1515/Jbcpp-2015-0118  0.492
2016 Hahn YK, Paris JJ, Lichtman AH, Hauser KF, Sim-Selley LJ, Selley DE, Knapp PE. Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain. Neurobiology of Disease. PMID 26845176 DOI: 10.1016/J.Nbd.2016.01.014  0.472
2016 Zhen J, Antonio T, Jacob JC, Grandy DK, Reith MEA, Dutta AK, Selley DE. Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors. Neurochemical Research. 41: 328-339. PMID 26718829 DOI: 10.1007/S11064-015-1808-6  0.427
2015 Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ, Dewey WL, Akbarali HI, Streicher JM, Selley DE. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) modulating the mu opioid receptor in a biased fashion. Acs Chemical Neuroscience. PMID 26716358 DOI: 10.1021/Acschemneuro.5B00245  0.474
2015 Lazenka MF, Tomarchio A, Lichtman AH, Greengard P, Flajolet M, Selley DE, Sim-Selley LJ. Role of dopamine type 1 receptors and DARPP-32 in Δ9-THC-mediated induction of ΔFosB in the mouse forebrain. The Journal of Pharmacology and Experimental Therapeutics. PMID 26099530 DOI: 10.1124/Jpet.115.224428  0.452
2015 Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW, Merritt CR, Wise LE, Abdullah RA, Selley DE, Sim-Selley LJ, Cravatt BF, Lichtman AH. Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice. The Journal of Pharmacology and Experimental Therapeutics. 354: 111-20. PMID 25998048 DOI: 10.1124/Jpet.115.222851  0.434
2015 Yuan Y, Zaidi SA, Stevens DL, Scoggins KL, Mosier PD, Kellogg GE, Dewey WL, Selley DE, Zhang Y. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands. Bioorganic & Medicinal Chemistry. 23: 1701-15. PMID 25783191 DOI: 10.1016/J.Bmc.2015.02.055  0.545
2015 Smith TH, Blume LC, Straiker A, Cox JO, David BG, McVoy JR, Sayers KW, Poklis JL, Abdullah RA, Egertová M, Chen CK, Mackie K, Elphick MR, Howlett AC, Selley DE. Cannabinoid receptor-interacting protein 1a modulates CB1 receptor signaling and regulation. Molecular Pharmacology. 87: 747-65. PMID 25657338 DOI: 10.1124/Mol.114.096495  0.776
2015 Blume LC, Eldeeb K, Bass CE, Selley DE, Howlett AC. Cannabinoid receptor interacting protein (CRIP1a) attenuates CB1R signaling in neuronal cells. Cellular Signalling. 27: 716-26. PMID 25446256 DOI: 10.1016/J.Cellsig.2014.11.006  0.48
2015 Altarifi AA, Yuan Y, Zhang Y, Selley DE, Negus SS. Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats. Psychopharmacology. 232: 815-24. PMID 25178814 DOI: 10.1007/S00213-014-3719-7  0.559
2014 Lazenka MF, David BG, Lichtman AH, Nestler EJ, Selley DE, Sim-Selley LJ. Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions. Biochemical Pharmacology. 91: 380-9. PMID 25093286 DOI: 10.1016/J.Bcp.2014.07.024  0.505
2014 Naydenov AV, Horne EA, Cheah CS, Swinney K, Hsu KL, Cao JK, Marrs WR, Blankman JL, Tu S, Cherry AE, Fung S, Wen A, Li W, Saporito MS, Selley DE, et al. ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice. Neuron. 83: 361-71. PMID 25033180 DOI: 10.1016/J.Neuron.2014.06.030  0.356
2014 Schlosburg JE, Kinsey SG, Ignatowska-Jankowska B, Ramesh D, Abdullah RA, Tao Q, Booker L, Long JZ, Selley DE, Cravatt BF, Lichtman AH. Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice. The Journal of Pharmacology and Experimental Therapeutics. 350: 196-204. PMID 24849924 DOI: 10.1124/Jpet.114.212753  0.535
2014 Morgan DJ, Davis BJ, Kearn CS, Marcus D, Cook AJ, Wager-Miller J, Straiker A, Myoga MH, Karduck J, Leishman E, Sim-Selley LJ, Czyzyk TA, Bradshaw HB, Selley DE, Mackie K. Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 5152-63. PMID 24719095 DOI: 10.1523/Jneurosci.3445-12.2014  0.485
2014 Ahmed MH, Kellogg GE, Selley DE, Safo MK, Zhang Y. Predicting the molecular interactions of CRIP1a-cannabinoid 1 receptor with integrated molecular modeling approaches. Bioorganic & Medicinal Chemistry Letters. 24: 1158-65. PMID 24461351 DOI: 10.1016/J.Bmcl.2013.12.119  0.507
2014 Emery SM, Alotaibi MR, Tao Q, Selley DE, Lichtman AH, Gewirtz DA. Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 348: 293-302. PMID 24259678 DOI: 10.1124/Jpet.113.205120  0.301
2014 Lazenka MF, Selley DE, Sim-Selley LJ. ΔFosB induction correlates inversely with CB₁ receptor desensitization in a brain region-dependent manner following repeated Δ⁹-THC administration. Neuropharmacology. 77: 224-33. PMID 24090766 DOI: 10.1016/J.Neuropharm.2013.09.019  0.404
2013 Yuan Y, Zaidi SA, Elbegdorj O, Aschenbach LC, Li G, Stevens DL, Scoggins KL, Dewey WL, Selley DE, Zhang Y. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity. Journal of Medicinal Chemistry. 56: 9156-69. PMID 24144240 DOI: 10.1021/Jm4012214  0.513
2013 Zaidi SA, Arnatt CK, He H, Selley DE, Mosier PD, Kellogg GE, Zhang Y. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: Application of the 'message-address' concept in development of mu opioid receptor selective antagonists Bioorganic and Medicinal Chemistry. 21: 6405-6413. PMID 24055076 DOI: 10.1016/J.Bmc.2013.08.042  0.566
2013 Yuan Y, Elbegdorj O, Beletskaya IO, Selley DE, Zhang Y. Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function. Bioorganic & Medicinal Chemistry Letters. 23: 5045-8. PMID 23948248 DOI: 10.1016/J.Bmcl.2013.07.043  0.467
2013 Selley DE, Welch SP, Sim-Selley LJ. Sphingosine lysolipids in the CNS: endogenous cannabinoid antagonists or a parallel pain modulatory system? Life Sciences. 93: 187-93. PMID 23782998 DOI: 10.1016/J.Lfs.2013.06.004  0.353
2013 Zhang Y, Elbegdorj O, Yuan Y, Beletskaya IO, Selley DE. Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives. Bioorganic & Medicinal Chemistry Letters. 23: 3719-22. PMID 23721804 DOI: 10.1016/J.Bmcl.2013.05.027  0.548
2013 Yuan Y, Arnatt CK, El-Hage N, Dever SM, Jacob JC, Selley DE, Hauser KF, Zhang Y. A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities. Medchemcomm. 4: 847-851. PMID 23682308 DOI: 10.1039/C3Md00080J  0.506
2013 Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, Lichtman AH. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. The Journal of Pharmacology and Experimental Therapeutics. 345: 492-501. PMID 23412396 DOI: 10.1124/Jpet.112.201426  0.493
2013 Blume LC, Bass CE, Childers SR, Dalton GD, Roberts DC, Richardson JM, Xiao R, Selley DE, Howlett AC. Striatal CB1 and D2 receptors regulate expression of each other, CRIP1A and δ opioid systems. Journal of Neurochemistry. 124: 808-20. PMID 23286559 DOI: 10.1111/Jnc.12139  0.436
2012 Yuan Y, Elbegdorj O, Chen J, Akubathini SK, Zhang F, Stevens DL, Beletskaya IO, Scoggins KL, Zhang Z, Gerk PM, Selley DE, Akbarali HI, Dewey WL, Zhang Y. Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents. Journal of Medicinal Chemistry. 55: 10118-29. PMID 23116124 DOI: 10.1021/Jm301247N  0.51
2012 Welch SP, Sim-Selley LJ, Selley DE. Sphingosine-1-phosphate receptors as emerging targets for treatment of pain. Biochemical Pharmacology. 84: 1551-62. PMID 22971335 DOI: 10.1016/J.Bcp.2012.08.010  0.482
2012 Lazenka MF, Selley DE, Sim-Selley LJ. Brain regional differences in CB1 receptor adaptation and regulation of transcription. Life Sciences. 92: 446-52. PMID 22940268 DOI: 10.1016/J.Lfs.2012.08.023  0.449
2012 Yuan Y, Arnatt CK, Li G, Haney KM, Ding D, Jacob JC, Selley DE, Zhang Y. Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5. Organic & Biomolecular Chemistry. 10: 2633-46. PMID 22354464 DOI: 10.1039/C2Ob06801J  0.523
2012 Nguyen PT, Schmid CL, Raehal KM, Selley DE, Bohn LM, Sim-Selley LJ. β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biological Psychiatry. 71: 714-24. PMID 22264443 DOI: 10.1016/J.Biopsych.2011.11.027  0.481
2012 Wiley JL, Selley DE, Wang P, Kottani R, Gadthula S, Mahadeven A. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CBâ‚‚ mechanism. The Journal of Pharmacology and Experimental Therapeutics. 340: 433-44. PMID 22085649 DOI: 10.1124/Jpet.111.187815  0.538
2011 Yuan Y, Li G, He H, Stevens DL, Kozak P, Scoggins KL, Mitra P, Gerk PM, Selley DE, Dewey WL, Zhang Y. Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists. Acs Chemical Neuroscience. 2: 346-51. PMID 22816021 DOI: 10.1021/Cn2000348  0.559
2011 Sim-Selley LJ, Cassidy MP, Sparta A, Zachariou V, Nestler EJ, Selley DE. Effect of ΔFosB overexpression on opioid and cannabinoid receptor-mediated signaling in the nucleus accumbens. Neuropharmacology. 61: 1470-6. PMID 21907220 DOI: 10.1016/J.Neuropharm.2011.08.046  0.563
2011 Yuan Y, Elbegdorj O, Chen J, Akubathini SK, Beletskaya IO, Selley DE, Zhang Y. Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 21: 5625-9. PMID 21788135 DOI: 10.1016/J.Bmcl.2011.06.135  0.537
2011 Hoot MR, Sim-Selley LJ, Selley DE, Scoggins KL, Dewey WL. Chronic neuropathic pain in mice reduces μ-opioid receptor-mediated G-protein activity in the thalamus. Brain Research. 1406: 1-7. PMID 21762883 DOI: 10.1016/J.Brainres.2011.06.023  0.55
2011 Wise LE, Varvel SA, Selley DE, Wiebelhaus JM, Long KA, Middleton LS, Sim-Selley LJ, Lichtman AH. delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory. Psychopharmacology. 217: 485-94. PMID 21559804 DOI: 10.1007/S00213-011-2305-5  0.31
2011 Kinsey SG, Mahadevan A, Zhao B, Sun H, Naidu PS, Razdan RK, Selley DE, Imad Damaj M, Lichtman AH. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology. 60: 244-51. PMID 20849866 DOI: 10.1016/J.Neuropharm.2010.09.004  0.531
2010 Huffman JW, Hepburn SA, Lyutenko N, Thompson AL, Wiley JL, Selley DE, Martin BR. 1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor. Bioorganic & Medicinal Chemistry. 18: 7809-15. PMID 20943404 DOI: 10.1016/J.Bmc.2010.09.061  0.5
2010 Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ, Thomas EA, Selley DE, Sim-Selley LJ, Liu QS, Lichtman AH, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nature Neuroscience. 13: 1113-9. PMID 20729846 DOI: 10.1038/Nn.2616  0.547
2010 Burston JJ, Wiley JL, Craig AA, Selley DE, Sim-Selley LJ. Regional enhancement of cannabinoid CB₁ receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure. British Journal of Pharmacology. 161: 103-12. PMID 20718743 DOI: 10.1111/J.1476-5381.2010.00870.X  0.36
2010 Smith TH, Sim-Selley LJ, Selley DE. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? British Journal of Pharmacology. 160: 454-66. PMID 20590557 DOI: 10.1111/J.1476-5381.2010.00777.X  0.768
2010 Nguyen PT, Selley DE, Sim-Selley LJ. Statistical Parametric Mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain Neuroimage. 52: 1243-1251. PMID 20451624 DOI: 10.1016/J.Neuroimage.2010.04.259  0.467
2010 Hoot MR, Sim-Selley LJ, Poklis JL, Abdullah RA, Scoggins KL, Selley DE, Dewey WL. Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice. Brain Research. 1339: 18-25. PMID 20380816 DOI: 10.1016/J.Brainres.2010.03.105  0.489
2010 Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, Selley DE, Lichtman AH, Sim-Selley LJ. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 1775-87. PMID 20357755 DOI: 10.1038/Npp.2010.44  0.788
2009 Sim-Selley LJ, Goforth PB, Mba MU, Macdonald TL, Lynch KR, Milstien S, Spiegel S, Satin LS, Welch SP, Selley DE. Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS. Journal of Neurochemistry. 110: 1191-202. PMID 19493165 DOI: 10.1111/J.1471-4159.2009.06202.X  0.488
2009 Li G, Aschenbach LC, He H, Selley DE, Zhang Y. 14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies. Bioorganic & Medicinal Chemistry Letters. 19: 1825-9. PMID 19217280 DOI: 10.1016/J.Bmcl.2008.12.093  0.548
2009 Li G, Aschenbach LC, Chen J, Cassidy MP, Stevens DL, Gabra BH, Selley DE, Dewey WL, Westkaemper RB, Zhang Y. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. Journal of Medicinal Chemistry. 52: 1416-27. PMID 19199782 DOI: 10.1021/Jm801272C  0.544
2009 Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH, Cravatt BF. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nature Chemical Biology. 5: 37-44. PMID 19029917 DOI: 10.1038/Nchembio.129  0.388
2009 Li G, Aschenbach LC, Chen J, Cassidy MP, Stevens DL, Gabra BH, Selley DE, Dewey WL, Westkaemper RB, Zhang Y. Corrections to design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective antagonists (Journal of Medicinal Chemistry (2009) 52, (1416) DOI 10.1021/jm801272c) Journal of Medicinal Chemistry. 52: 8057. DOI: 10.1021/Jm9016224  0.442
2008 Wiley JL, Kendler SH, Burston JJ, Howard DR, Selley DE, Sim-Selley LJ. Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. Neuropharmacology. 55: 1183-90. PMID 18708079 DOI: 10.1016/J.Neuropharm.2008.07.026  0.467
2008 Burston JJ, Sim-Selley LJ, Harloe JP, Mahadevan A, Razdan RK, Selley DE, Wiley JL. N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. The Journal of Pharmacology and Experimental Therapeutics. 327: 546-53. PMID 18682568 DOI: 10.1124/Jpet.108.141382  0.41
2008 Perrotti LI, Weaver RR, Robison B, Renthal W, Maze I, Yazdani S, Elmore RG, Knapp DJ, Selley DE, Martin BR, Sim-Selley L, Bachtell RK, Self DW, Nestler EJ. Distinct patterns of DeltaFosB induction in brain by drugs of abuse. Synapse (New York, N.Y.). 62: 358-69. PMID 18293355 DOI: 10.1002/Syn.20500  0.31
2008 McKinney DL, Cassidy MP, Collier LM, Martin BR, Wiley JL, Selley DE, Sim-Selley LJ. Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. The Journal of Pharmacology and Experimental Therapeutics. 324: 664-73. PMID 17967938 DOI: 10.1124/Jpet.107.130328  0.531
2007 Niehaus JL, Liu Y, Wallis KT, Egertová M, Bhartur SG, Mukhopadhyay S, Shi S, He H, Selley DE, Howlett AC, Elphick MR, Lewis DL. CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a. Molecular Pharmacology. 72: 1557-66. PMID 17895407 DOI: 10.1124/Mol.107.039263  0.545
2007 Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. The Journal of Pharmacology and Experimental Therapeutics. 323: 346-55. PMID 17646430 DOI: 10.1124/Jpet.107.119560  0.412
2007 Smith PA, Selley DE, Sim-Selley LJ, Welch SP. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. European Journal of Pharmacology. 571: 129-37. PMID 17603035 DOI: 10.1016/J.Ejphar.2007.06.001  0.542
2007 Sim-Selley LJ, Scoggins KL, Cassidy MP, Smith LA, Dewey WL, Smith FL, Selley DE. Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance. British Journal of Pharmacology. 151: 1324-33. PMID 17572699 DOI: 10.1038/Sj.Bjp.0707328  0.511
2006 Sim-Selley LJ, Schechter NS, Rorrer WK, Dalton GD, Hernandez J, Martin BR, Selley DE. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Molecular Pharmacology. 70: 986-96. PMID 16760363 DOI: 10.1124/Mol.105.019612  0.524
2006 Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Molecular Pharmacology. 70: 41-50. PMID 16571654 DOI: 10.1124/Mol.105.020552  0.575
2006 Zachariou V, Bolanos CA, Selley DE, Theobald D, Cassidy MP, Kelz MB, Shaw-Lutchman T, Berton O, Sim-Selley LJ, Dileone RJ, Kumar A, Nestler EJ. An essential role for DeltaFosB in the nucleus accumbens in morphine action. Nature Neuroscience. 9: 205-11. PMID 16415864 DOI: 10.1038/Nn1636  0.442
2005 Huffman JW, Szklennik PV, Almond A, Bushell K, Selley DE, He H, Cassidy MP, Wiley JL, Martin BR. 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorganic & Medicinal Chemistry Letters. 15: 4110-3. PMID 16005223 DOI: 10.1016/J.Bmcl.2005.06.008  0.51
2005 Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K, Thompson AL, Bushell S, Tartal C, Hurst DP, Reggio PH, Selley DE, Cassidy MP, Wiley JL, Martin BR. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorganic & Medicinal Chemistry. 13: 89-112. PMID 15582455 DOI: 10.1016/J.Bmc.2004.09.050  0.533
2004 Cichewicz DL, Cox ML, Welch SP, Selley DE, Sim-Selley LJ. Mu and delta opioid-stimulated [35S]GTP gamma S binding in brain and spinal cord of polyarthritic rats. European Journal of Pharmacology. 504: 33-8. PMID 15507218 DOI: 10.1016/J.Ejphar.2004.09.050  0.486
2004 Schwindinger WF, Giger KE, Betz KS, Stauffer AM, Sunderlin EM, Sim-Selley LJ, Selley DE, Bronson SK, Robishaw JD. Mice with deficiency of G protein gamma3 are lean and have seizures. Molecular and Cellular Biology. 24: 7758-68. PMID 15314181 DOI: 10.1128/Mcb.24.17.7758-7768.2004  0.341
2004 Selley DE, Cassidy MP, Martin BR, Sim-Selley LJ. Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum. Molecular Pharmacology. 66: 1275-84. PMID 15286206 DOI: 10.1124/Mol.104.000604  0.527
2004 Martin BR, Sim-Selley LJ, Selley DE. Signaling pathways involved in the development of cannabinoid tolerance. Trends in Pharmacological Sciences. 25: 325-30. PMID 15165748 DOI: 10.1016/J.Tips.2004.04.005  0.5
2004 Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. The Journal of Pharmacology and Experimental Therapeutics. 308: 547-54. PMID 14600248 DOI: 10.1124/Jpet.103.058602  0.574
2003 Zachariou V, Georgescu D, Sanchez N, Rahman Z, DiLeone R, Berton O, Neve RL, Sim-Selley LJ, Selley DE, Gold SJ, Nestler EJ. Essential role for RGS9 in opiate action. Proceedings of the National Academy of Sciences of the United States of America. 100: 13656-61. PMID 14595021 DOI: 10.1073/Pnas.2232594100  0.534
2003 Rahman Z, Schwarz J, Gold SJ, Zachariou V, Wein MN, Choi KH, Kovoor A, Chen CK, DiLeone RJ, Schwarz SC, Selley DE, Sim-Selley LJ, Barrot M, Luedtke RR, Self D, et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron. 38: 941-52. PMID 12818179 DOI: 10.1016/S0896-6273(03)00321-0  0.452
2003 Selley DE, Herbert JT, Morgan D, Cook CD, Picker MJ, Sim-Selley LJ. Effect of strain and sex on mu opioid receptor-mediated G-protein activation in rat brain. Brain Research Bulletin. 60: 201-8. PMID 12754081 DOI: 10.1016/S0361-9230(03)00014-5  0.448
2002 Smith FL, Javed R, Elzey MJ, Welch SP, Selley D, Sim-Selley L, Dewey WL. Prolonged reversal of morphine tolerance with no reversal of dependence by protein kinase C inhibitors. Brain Research. 958: 28-35. PMID 12468027 DOI: 10.1016/S0006-8993(02)03394-2  0.413
2002 Sim-Selley LJ, Sharpe AL, Vogt LJ, Brunk LK, Selley DE, Samson HH. Effect of ethanol self-administration on mu- and delta-opioid receptor-mediated G-protein activity. Alcoholism, Clinical and Experimental Research. 26: 688-94. PMID 12045478 DOI: 10.1111/J.1530-0277.2002.Tb02592.X  0.442
2001 Selley DE, Cao CC, Sexton T, Schwegel JA, Martin TJ, Childers SR. mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochemical Pharmacology. 62: 447-55. PMID 11448454 DOI: 10.1016/S0006-2952(01)00689-X  0.583
2001 Selley DE, Rorrer WK, Breivogel CS, Zimmer AM, Zimmer A, Martin BR, Sim-Selley LJ. Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation. Journal of Neurochemistry. 77: 1048-57. PMID 11359870 DOI: 10.1046/J.1471-4159.2001.00308.X  0.517
2001 Sim-Selley LJ, Brunk LK, Selley DE. Inhibitory effects of SR141716A on G-protein activation in rat brain. European Journal of Pharmacology. 414: 135-43. PMID 11239913 DOI: 10.1016/S0014-2999(01)00784-1  0.545
2000 Selley DE, Cao CC, Liu Q, Childers SR. Effects of sodium on agonist efficacy for G-protein activation in μ-opioid receptor-transfected CHO cells and rat thalamus British Journal of Pharmacology. 130: 987-996. PMID 10882382 DOI: 10.1038/Sj.Bjp.0703382  0.594
2000 Sim-Selley LJ, Selley DE, Vogt LJ, Childers SR, Martin TJ. Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 4555-62. PMID 10844025 DOI: 10.1523/Jneurosci.20-12-04555.2000  0.581
2000 Maher CE, Selley DE, Childers SR. Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions Biochemical Pharmacology. 59: 1395-1401. PMID 10751548 DOI: 10.1016/S0006-2952(00)00272-0  0.552
2000 Sim-Selley LJ, Vogt LJ, Xiao R, Childers SR, Selley DE. Region-specific changes in 5-HT(1A) receptor-activated G-proteins in rat brain following chronic buspirone. European Journal of Pharmacology. 389: 147-53. PMID 10688978 DOI: 10.1016/S0014-2999(99)00875-4  0.443
1998 Breivogel CS, Selley DE, Childers SR. Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity Journal of Biological Chemistry. 273: 16865-16873. PMID 9642247 DOI: 10.1074/Jbc.273.27.16865  0.423
1998 Cunningham MJ, Fang Y, Selley DE, Kelly MJ. mu-Opioid agonist-stimulated [35S]GTPgammaS binding in guinea pig hypothalamus: effects of estrogen. Brain Research. 791: 341-6. PMID 9593984 DOI: 10.1016/S0006-8993(98)00201-7  0.574
1998 Sim LJ, Liu Q, Childers SR, Selley DE. Endomorphin-stimulated [35S]GTPγs binding in rat brain: Evidence for partial agonist activity at μ-opioid receptors Journal of Neurochemistry. 70: 1567-1576. PMID 9523574 DOI: 10.1046/J.1471-4159.1998.70041567.X  0.536
1998 Selley DE, Breivogel CS, Childers SR. Opioid inhibition of adenylyl cyclase in membranes from pertussis toxin- related NG108-15 cells Journal of Receptor and Signal Transduction Research. 18: 25-50. PMID 9493566 DOI: 10.3109/10799899809039163  0.541
1997 Martin TJ, Sim LJ, Selley DE, DeMontis MG, Childers SR. Effects of intracerebroventricular administration of β-funaltrexamine on DAMGO-stimulated [35S]GTP-γ-S binding in rat brain sections Synapse. 27: 177-182. PMID 9329153 DOI: 10.1002/(Sici)1098-2396(199711)27:3<177::Aid-Syn3>3.0.Co;2-A  0.525
1997 Sim LJ, Selley DE, Childers SR. Autoradiographic visualization in brain of receptor-G protein coupling using [35S]GTP gamma S binding. Methods in Molecular Biology (Clifton, N.J.). 83: 117-132. PMID 9210141 DOI: 10.1385/0-89603-495-X:117  0.432
1997 Breivogel CS, Selley DE, Childers SR. Acute and chronic effects of opioids on δ and μ receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes Journal of Neurochemistry. 68: 1462-1472. PMID 9084416 DOI: 10.1046/J.1471-4159.1997.68041462.X  0.577
1997 Selley DE, Nestler EJ, Breivogel CS, Childers SR. Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: Decrease in activity after chronic morphine treatment Brain Research. 746: 10-18. PMID 9037478 DOI: 10.1016/S0006-8993(96)01125-0  0.555
1997 Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR. μ-Opioid receptor-stimulated guanosine-5'-O-(γ-thio)-triphosphate binding in rat thalamus and cultured cell lines: Signal transduction mechanisms underlying agonist efficacy Molecular Pharmacology. 51: 87-96. PMID 9016350 DOI: 10.1124/Mol.51.1.87  0.577
1996 Sim LJ, Selley DE, Xiao R, Childers SR. Differences in G-protein activation by μ- and δ-opioid, and cannabinoid, receptors in rat striatum European Journal of Pharmacology. 307: 97-105. PMID 8831110 DOI: 10.1016/0014-2999(96)00211-7  0.594
1996 Sim LJ, Selley DE, Dworkin SI, Childers SR. Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 2684-92. PMID 8786444 DOI: 10.1523/Jneurosci.16-08-02684.1996  0.505
1996 Selley DE, Stark S, Sim LJ, Childers SR. Cannabinoid receptor stimulation of guanosine-5'-O-(3- [35S]thio)triphosphate binding in rat brain membranes Life Sciences. 59: 659-668. PMID 8761016 DOI: 10.1016/0024-3205(96)00347-5  0.503
1995 Sim LJ, Selley DE, Childers SR. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5′-[γ-[35S]thio]-triphosphate binding Proceedings of the National Academy of Sciences of the United States of America. 92: 7242-7246. PMID 7638174 DOI: 10.1073/Pnas.92.16.7242  0.584
1995 Selley DE, Breivogel CS, Childers SR. MECHANISMS OF LOW pH PRETREATMENT-INDUCED INCREASE IN OPIOID AGONIST EFFICACY: [35S]GTPγS BINDING STUDIES Analgesia. 1: 715-718. DOI: 10.3727/107156995819563113  0.325
1994 Sim LJ, Selley DE, Tsai KP, Morris M. D2 inhibition of stimulated Fos immunoreactivity in cultured tyrosine hydroxylase-ir hypothalamic neurons Brain Research. 651: 311-316. PMID 7922580 DOI: 10.1016/0006-8993(94)90711-0  0.379
1994 Selley DE, Breivogel CS, Childers SR. Opioid inhibition of adenylyl cyclase remaining after pertussis toxin treatment of NG108-15 cells: Possible involvement of tightly bound GTP. Regulatory Peptides. 54: 265-266. DOI: 10.1016/0167-0115(94)90491-X  0.513
1994 Selley DE, Childers SR, Chang KJ. BW373U86, a non-peptide δ opioid agonist with novel receptor-protein-mediated actions Regulatory Peptides. 53: S27-S28. DOI: 10.1016/0167-0115(94)90224-0  0.43
1989 Selley DE, Bidlack JM. Guanine nucleotide regulation of [125I]beta-endorphin binding to NG108-15 and SK-N-SH cell membranes: specific cation requirements. Brain Research. 493: 23-32. PMID 2550106 DOI: 10.1016/0006-8993(89)90996-7  0.302
Show low-probability matches.